AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
AC Immune SA (NASDAQ: ACIU) said it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of its Phase 2 VacSYn trial of ACI-7104 in early Parkinson’s disease by 2 years to assess long-term safety and efficacy. Final Part 1 results (to week 104) are expected in H2 2026.
How this was made
The 30-second read
Why it matters
The grant funds extending Part 1 for an additional 2 years to generate long-term safety/efficacy data, with final Part 1 results expected in H2 2026 (week-104).
Market read
Non-dilutive funding plus a longer follow-up window can improve the quality of the clinical evidence base into the next major readout (H2 2026).
What to watch
Traders may discount the news if the trial extension does not alter endpoints or if interim signals later prove less durable than hoped; also watch for any future dilution/financing needs despite non-dilutive funding.
Background
VacSYn Part 1 is a Phase 2 study in early Parkinson’s using ACI-7104 (anti-alpha-syn active immunotherapy); positive interim results were reported in Dec 2025.
Ticker impact
AC Immune announced a $4M grant to extend Part 1 of its Phase 2 VacSYn trial of ACI-7104 for 2 additional years in early Parkinson’s.
Near-term sentiment likely positive; material upside depends on how the extended dataset de-risks disease-modifying claims by H2 2026.
The article discloses a concrete, time-bound trial extension funded by a specific $4M grant, but it does not provide new efficacy results or guidance beyond the planned H2 2026 final data.
Market effects
Reinforces investor focus on anti-alpha-synuclein immunotherapies and the value of long-term safety datasets in early PD.
Primarily impacts US-listed biotech sentiment; grant is from a private foundation with no stated geographic market effects.
Highlights continued global funding and momentum for neurodegenerative precision-prevention programs.
Counterpoint
A $4M grant may be helpful but is unlikely to change valuation materially versus the larger question of whether extended follow-up confirms disease-modifying benefit.
Key entities
- companyAC Immune SA
Clinical-stage biopharmaceutical company developing ACI-7104 for early Parkinson’s via VacSYn Phase 2.
- drug_programACI-7104
Anti-alpha-synuclein active immunotherapy; Part 1 extension targets long-term safety/efficacy in early PD.
- funderVijay and Marie Goradia Charitable Foundation
Provides a $4M research grant to support the VacSYn Part 1 extension.
